clindamycin is an approved drug (FDA (1970))
Compound class:
Synthetic organic
Comment: Clindamycin is a semisynthetic lincosamide antibacterial with broad-spectrum activity. The compound also has antimalarial activity.
Clindamycin is one of the key access group antibacterials on the World Health Organization's Model List of Essential Medicines (link provided in the Classification table, under the Summary tab below). The Malaria tab on this ligand page provides additional curator comments of relevance to the Guide to MALARIA PHARMACOLOGY. |
|
Bioactivity Comments |
Clindamycin, like a number of other antibacterials including azithromycin and doxycycline, kills the malaria parasite in the lifecycle after treatment starts [1]. Consistent with this slow clinical action, the results provided in the table below show that clindamycin is more potent in vitro against erythrocytic stage parasites when assessed two asexual life cycles after the initiation of treatment. |
Whole organism assay data | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click on species/strain names for details | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|